The progression of incretin-based obesity therapy has followed a recognizable arc. First came single-receptor GLP-1 agonists, which proved the concept. Then tirzepatide demonstrated that adding GIP receptor activation to GLP-1 could push average weight loss past 20%. Now retatrutide adds a third receptor — glucagon — and the Phase 2 and early Phase 3 data suggest another meaningful step forward.
This comparison matters because both compounds come from Eli Lilly, both target GIP and GLP-1, and the logical question is: what does the glucagon receptor actually add, and is it worth the trade-offs? The answer is nuanced and still evolving, but the evidence available in early 2026 gives us enough to draw meaningful conclusions.
A critical note before proceeding: the confirmed Phase 2 result for retatrutide is 24.2% weight loss at 48 weeks from the peer-reviewed NEJM publication (Jastreboff et al., 2023). The 28.7% figure comes from TRIUMPH-4 Phase 3 topline data announced in December 2025, from a specific knee osteoarthritis patient population. Full peer-reviewed publication of these Phase 3 results is pending. We cite these figures with their appropriate caveats throughout this guide.
Quick Comparison
- Receptor targets: Tirzepatide hits GLP-1 and GIP; Retatrutide hits GLP-1, GIP, and Glucagon.
- Classification: Tirzepatide is a dual agonist; Retatrutide is a triple agonist.
- FDA approval: Tirzepatide is approved (Mounjaro 2022, Zepbound 2023); Retatrutide is not — it remains investigational.
- Brand names: Tirzepatide is sold as Mounjaro (diabetes) and Zepbound (obesity); Retatrutide has no brand name (investigational designation: LY3437943).
- Manufacturer: Both are from Eli Lilly.
- Maximum studied dose: 15 mg weekly for tirzepatide; 12 mg weekly for retatrutide.
- Weight loss (landmark trial): Tirzepatide achieved 22.5% at 72 weeks in SURMOUNT-1 (efficacy estimand); Retatrutide achieved 24.2% at 48 weeks in the Phase 2 NEJM 2023 trial.
- Phase 3 topline data: Tirzepatide has an extensive Phase 3 program complete; Retatrutide's TRIUMPH-4 showed 28.7% at 68 weeks (pending full publication; knee osteoarthritis population).
- Cardiovascular outcomes data: Tirzepatide's SURPASS-CVOT showed noninferiority to dulaglutide; Retatrutide has no CV outcomes data yet.
- Liver fat reduction: Tirzepatide produces meaningful reduction but this was not a primary endpoint; Retatrutide achieved up to 82–86% relative reduction in the Phase 2 MASLD cohort.
- Dosing: Once weekly for both.
- Titration to max dose: 20 weeks for tirzepatide; approximately 16 weeks for retatrutide (Phase 2 protocol).
- Notable unique side effect: Tirzepatide has none specific to its dual mechanism; Retatrutide carries dysesthesia at up to 20.9% of participants at 12 mg in Phase 3.
- Availability: Tirzepatide is available by prescription and widely accessible; Retatrutide is limited to clinical trials.
- WADA status: Tirzepatide is under monitoring but not prohibited; Retatrutide is not explicitly listed — exercise caution.
Tirzepatide: Strengths and Best Uses
Tirzepatide represents the current evidence-backed ceiling for approved obesity pharmacotherapy. Its dual GIP/GLP-1 mechanism consistently outperforms GLP-1 monotherapy, and its clinical trial program is among the most extensive in the field.
The Dual Agonist Mechanism
Tirzepatide is a 39-amino-acid synthetic peptide designed to activate both the GIP and GLP-1 receptors simultaneously. Both receptors are expressed on pancreatic beta cells, where their activation potentiates glucose-dependent insulin secretion. The glucose-dependent nature of this mechanism is clinically important: insulin release occurs only when blood glucose is elevated, substantially minimizing hypoglycemia risk.
GLP-1 receptor activation in the hypothalamus and brainstem suppresses appetite and food reward pathways. GIP receptor activation adds a complementary signal through partially distinct downstream pathways — particularly relevant in adipose tissue, where GIP receptors mediate effects on lipid storage and fat oxidation, and in hypothalamic regions governing energy balance. The combination produces additive or synergistic effects that exceed what GLP-1 agonism alone achieves.
Delayed gastric emptying (GLP-1 mediated) contributes to prolonged satiety and blunted post-meal glucose excursions. Together, these mechanisms reduce caloric intake while improving insulin sensitivity and lipid metabolism.
SURMOUNT-1: The Landmark Result
The SURMOUNT-1 trial enrolled 2,539 adults without diabetes with a BMI of 30 or greater (or 27 or greater with a weight-related comorbidity). At 72 weeks:
- 5 mg dose: 16.0% weight reduction (efficacy estimand)
- 10 mg dose: 21.4% weight reduction
- 15 mg dose: 22.5% weight reduction
- Placebo: 2.4% weight reduction
On the treatment-policy estimand (which includes all participants regardless of adherence): 15.0%, 19.5%, and 20.9% respectively. At the 15 mg dose, 63% of participants achieved at least 20% weight loss, and a secondary analysis showed 36% achieved at least 25%.
SURMOUNT-2, in participants with type 2 diabetes, demonstrated 12.8% to 14.7% weight loss — smaller than the non-diabetic cohort but still clinically significant alongside substantial HbA1c improvements.Head-to-Head vs Semaglutide: SURMOUNT-5
The SURMOUNT-5 trial directly compared tirzepatide to semaglutide in 751 adults with obesity over 72 weeks. Tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide — a 6.5 percentage point advantage. This trial established tirzepatide's superiority over the leading GLP-1 monotherapy.
FDA Approval and Real-World Track Record
Tirzepatide's regulatory status is one of its clearest advantages in a comparison with retatrutide. Mounjaro was approved for type 2 diabetes in May 2022. Zepbound was approved for chronic weight management in November 2023. This approval history means tirzepatide has entered clinical practice, accumulated real-world prescribing experience, and been prescribed to hundreds of thousands of patients under physician supervision.
The safety data from large-scale real-world use provides a layer of evidence that no Phase 2 trial, however well-designed, can match.Limitations
Weight regain after discontinuation is significant. The SURMOUNT-4 trial showed participants regained approximately two-thirds of lost weight within one year of stopping, consistent with the class as a whole. Tirzepatide treats obesity chronically rather than curing it. The GI side effect profile — nausea (up to 30% at higher doses), diarrhea, constipation, vomiting — is dose-dependent and concentrated during escalation phases. Lean mass loss (approximately 25 to 40% of total weight lost may be lean tissue) requires mitigation through adequate protein intake and resistance training.
No completed placebo-controlled cardiovascular outcomes trial exists specifically for tirzepatide in an obesity population, which limits cardiovascular benefit claims compared to semaglutide's SELECT data.
Retatrutide: Strengths and Best Uses
Retatrutide represents the next generation of incretin-based therapy. The data from its Phase 2 program and early Phase 3 readouts are genuinely remarkable, but they come with important caveats about evidence maturity and regulatory status.
The Triple Agonist Mechanism
Retatrutide (LY3437943) is a 39-amino-acid peptide conjugated to a fatty diacid moiety giving it a half-life of approximately 6 days, supporting once-weekly dosing. Its receptor potency profile is distinctive: approximately 8.9-fold greater potency at the GIP receptor compared to its endogenous ligand, with somewhat lower relative potency at the GLP-1 and glucagon receptors (0.4- and 0.3-fold respectively). This GIP-dominant potency profile differs from tirzepatide's more balanced dual agonism.
The GLP-1 and GIP mechanisms in retatrutide function similarly to tirzepatide: appetite suppression, glucose-dependent insulin secretion, delayed gastric emptying, and lipid metabolism effects. The glucagon receptor component is where retatrutide diverges.
What the Glucagon Receptor Adds
Glucagon has historically been viewed as a counter-regulatory hormone — the signal that raises blood glucose when it drops too low. Its inclusion in an anti-obesity medication seems counterintuitive. The key insight is that when glucagon receptor agonism is combined with GLP-1 and GIP activation (which both suppress glucagon-induced hyperglycemia through insulin stimulation), the hyperglycemic risk is counterbalanced, while the metabolic benefits of glucagon activation remain.
Those metabolic benefits are significant. Glucagon receptor agonism increases hepatic energy expenditure through enhanced fatty acid oxidation, stimulates thermogenesis, and shifts the body's metabolic substrate utilization toward fat burning. In practical terms, retatrutide both suppresses energy intake (through the GLP-1/GIP component) and increases energy expenditure (through the glucagon component). This dual-strategy approach is the theoretical basis for its greater weight loss.
The hepatic effects are particularly striking. Glucagon drives direct liver fat oxidation, which likely explains retatrutide's extraordinary effects on hepatic steatosis in dedicated MASLD trials (discussed below).
Phase 2 Clinical Evidence
The pivotal Phase 2 trial (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity (BMI ≥30 or ≥27 with comorbidities) in a randomized, double-blind, placebo-controlled design. At 48 weeks, results by dose group were:
- 12 mg: 24.2% weight loss
- 8 mg: 22.8% weight loss
- 4 mg: 17.1% weight loss
- Placebo: 2.1% weight loss
Response thresholds at the 12 mg dose at 48 weeks: 100% of participants achieved at least 5% weight loss; 93% achieved at least 10%; 83% achieved at least 15%. 63% achieved ≥20%; 48% achieved ≥25%; 26% achieved ≥30%.
A critical observation from the Phase 2 data: weight loss curves had not plateaued at 48 weeks. This suggests continued treatment would produce further reductions — consistent with the higher numbers seen in longer Phase 3 follow-up.
Phase 3: TRIUMPH-4 Topline Data
The TRIUMPH-4 Phase 3 trial, which enrolled patients with obesity and knee osteoarthritis, reported topline results in December 2025. The 12 mg dose produced mean weight loss of 28.7% at 68 weeks, with 23.7% of participants achieving ≥35% weight loss. The 9 mg dose produced 26.4% weight loss.
Several important caveats apply:
- TRIUMPH-4 enrolled a specific population (obesity plus knee osteoarthritis), not a general obesity cohort
- These are topline results from a press release; full peer-reviewed publication is pending
- Direct comparison to SURMOUNT-1 or STEP 1 (which enrolled general obesity populations) carries population confounding limitations
Until full Phase 3 data across the TRIUMPH program are published and reviewed, the confirmed peer-reviewed benchmark for retatrutide remains the Phase 2 result of 24.2% at 48 weeks.
Extraordinary Liver Fat Reduction
Retatrutide's effects on hepatic steatosis deserve specific attention because they substantially exceed what tirzepatide or semaglutide produce. In a dedicated Phase 2a MASLD trial (Sanyal et al., Nature Medicine 2024), participants with metabolic dysfunction-associated steatotic liver disease and at least 10% baseline liver fat experienced:
- 12 mg dose: 82.4% relative liver fat reduction at 24 weeks, extending to 86% at 48 weeks
- 93% of participants at the highest dose achieved resolution of steatosis (liver fat below 5%)
For context, semaglutide reduces liver fat by approximately 40 to 60% in NASH/MASLD populations — clinically meaningful, but not approaching retatrutide's near-complete resolution. Tirzepatide produces comparable or modestly greater liver fat reduction to semaglutide, also falling well short of retatrutide's effect. The glucagon-driven direct hepatic fatty acid oxidation mechanism appears to be a qualitatively different intervention for MASLD.
Head-to-Head: Mechanism Comparison
Shared Foundation: GLP-1 + GIP
Both tirzepatide and retatrutide engage the two major incretin receptors that have proven central to effective obesity pharmacotherapy. The superior performance of dual GIP/GLP-1 agonism over GLP-1 monotherapy is now established by tirzepatide's clinical record. Both compounds produce appetite suppression, gastric motility effects, glucose-dependent insulin secretion enhancement, and GIP-mediated improvements in lipid metabolism and fat oxidation.
The Glucagon Dimension
Retatrutide's glucagon receptor activation represents a genuinely additive mechanism rather than an amplification of existing pathways. Where tirzepatide reduces caloric intake through satiety and appetite suppression, retatrutide simultaneously increases caloric expenditure through thermogenesis and hepatic fat oxidation. This bidirectional energy balance intervention is the most plausible explanation for retatrutide's apparent weight loss advantage over tirzepatide.
However, glucagon agonism is not without complexity. Glucagon receptors are expressed in the heart, and a dose-dependent increase in heart rate has been observed in retatrutide Phase 2 trials (peaking at week 24, then declining). This cardiovascular effect requires longer-term monitoring in the Phase 3 program. The absence of completed cardiovascular outcomes data for retatrutide means its cardiac risk-benefit profile remains incompletely characterized — in contrast to tirzepatide's SURPASS-CVOT results and semaglutide's SELECT data.
Side Effect Differentiation
The shared GI side effect profile (nausea, diarrhea, vomiting, constipation during escalation) applies to both. The unique differentiation is dysesthesia with retatrutide — tingling, numbness, or burning sensations reported in 8.8% of Phase 3 participants on 9 mg and 20.9% on 12 mg, compared to 0.7% on placebo. This is not a class effect seen with tirzepatide and may relate to glucagon receptor activity in peripheral sensory pathways. Phase 3 reporting characterized these events as generally mild and not leading to treatment discontinuation, but the frequency at the highest dose is substantial and will require ongoing monitoring.
Which Should You Choose?
The practical question for anyone currently managing obesity with or considering pharmacotherapy.
- Need treatment now with proven efficacy: Tirzepatide. FDA-approved, widely available, and backed by an extensive Phase 3 dataset.
- Primary goal — maximum weight loss with an approved therapy: Tirzepatide 15 mg. It produces the greatest weight loss of any currently approved medication.
- Significant hepatic steatosis / MASLD: Retatrutide (if available via clinical trial). The Phase 2 liver fat data is unmatched by any existing therapy.
- Plateaued on semaglutide: Tirzepatide. Its dual mechanism produces further weight loss in prior GLP-1 non-responders.
- Cardiovascular risk reduction is the primary goal: Semaglutide. The SELECT trial provides placebo-controlled CV outcome data that tirzepatide and retatrutide currently lack.
- Willing to enroll in a clinical trial for cutting-edge therapy: Retatrutide (trial enrollment). This provides access to the most potent obesity pharmacotherapy currently in clinical development.
- Concerned about dysesthesia or peripheral sensory effects: Tirzepatide. Retatrutide's 20.9% dysesthesia rate at 12 mg is a meaningful consideration.
- Type 2 diabetes requiring optimal glycemic control: Tirzepatide. Approved for diabetes and demonstrated greater A1C reduction than semaglutide in SURPASS-2.
The decision framework is relatively straightforward: tirzepatide is the choice for anyone who needs treatment today through established clinical channels. Retatrutide is the answer for those who can access clinical trials and have clinical profiles that its unique mechanisms would specifically benefit — particularly severe obesity with hepatic steatosis, or patients who have not achieved sufficient weight loss with dual agonism.
It is important to note that retatrutide is currently not obtainable through any approved or legal channel outside of active trial participation. Research-grade retatrutide sold through peptide vendors cannot have its purity, dosing accuracy, or sterility verified, and using it outside clinical monitoring means accepting unknown risks without medical oversight.
Safety Comparison
Tirzepatide: Well-Characterized Safety Profile
Tirzepatide's safety data come from a large Phase 3 program across multiple trials, with thousands of participants and follow-up extending to 72 weeks and beyond. The side effect profile is well-characterized and expected for the class.
Common adverse events include nausea (up to 30% at higher doses during escalation), diarrhea, constipation, vomiting, and decreased appetite. Less common effects include injection-site reactions, fatigue, and hair loss (typically temporary and related to caloric restriction rather than the drug directly). Rare but serious risks include pancreatitis, gallbladder disease, and the class-wide boxed warning regarding thyroid C-cell tumor risk based on rodent data. Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2.
The SURPASS-CVOT trial demonstrated cardiovascular noninferiority to dulaglutide in type 2 diabetes patients with atherosclerotic cardiovascular disease, and a 16% reduction in all-cause mortality relative to dulaglutide (though the primary MACE endpoint did not achieve statistical superiority). Real-world prescribing since 2022 has not generated unexpected safety signals.
Retatrutide: Emerging Safety Profile
Retatrutide's safety data come from Phase 2 trials and TRIUMPH-4 Phase 3 topline reports. The GI side effect profile is broadly comparable to tirzepatide: nausea (14 to 45% depending on dose in Phase 2), diarrhea (9 to 20%), vomiting (3 to 26%), constipation (7 to 16%), and decreased appetite (13 to 31%). Notably, participants who bypassed dose escalation experienced nearly double the GI side effect rates — emphasizing the non-negotiable importance of slow titration for this drug.
The distinguishing safety signal is dysesthesia. Phase 3 TRIUMPH-4 data reported this side effect in 8.8% of participants at 9 mg and 20.9% at 12 mg, compared to 0.7% with placebo. Characterization as generally mild and not leading to discontinuation is reassuring, but 20.9% represents a frequency that clinicians and patients will need to weigh. Whether this effect diminishes with extended use, and its mechanism (likely glucagon receptor mediated), requires further study.
A dose-dependent mild increase in heart rate was observed in Phase 2, peaking around week 24 and declining thereafter. This is being monitored in Phase 3 cardiovascular safety analyses. No increase in major adverse cardiovascular events has been reported to date.
Serious adverse events in Phase 2 occurred at comparable rates to placebo (4% each). However, retatrutide lacks the years of post-marketing safety data and large-population real-world experience that tirzepatide has begun to accumulate.
Shared Safety Considerations
Both drugs carry the incretin-class boxed warning regarding thyroid C-cell tumor risk observed in rodent studies. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Both produce lean mass loss (25 to 40% of total weight lost) that requires mitigation through adequate protein intake and resistance training. Weight regain after discontinuation is expected for both, consistent with the chronic nature of obesity treatment.
The quality risk from unregulated sources applies particularly to retatrutide: there is currently no legal, approved formulation, meaning any research-grade product sold by peptide vendors operates entirely outside regulatory oversight.
The Regulatory and Access Reality
Tirzepatide is available by prescription in the United States under two FDA-approved indications: Mounjaro for type 2 diabetes (May 2022) and Zepbound for chronic weight management (November 2023). Commercial insurance coverage is available for both, with manufacturer savings programs offering Zepbound single-dose vials at $299 to $449 per month through LillyDirect for eligible patients.
Retatrutide's development timeline as of early 2026:
- Phase 2 published: June 2023 (NEJM)
- Phase 3 TRIUMPH-4 topline data: December 2025
- Remaining Phase 3 completions projected: mid-2026
- NDA submission expected: late 2026
- Potential FDA approval: mid to late 2027 (Priority Review could accelerate this)
For a full comparison of semaglutide, tirzepatide, and retatrutide together, see the semaglutide vs retatrutide guide and the semaglutide vs tirzepatide guide.
Conclusion
The tirzepatide-versus-retatrutide comparison is one of the most scientifically interesting in obesity pharmacology — because both drugs share a common GIP/GLP-1 foundation, and the central question is what the third receptor (glucagon) actually delivers.
The answer from available data is: more weight loss, superior liver fat reduction, and a unique side effect profile. The Phase 2 data showing 24.2% weight loss at 48 weeks, and TRIUMPH-4 topline data showing 28.7% at 68 weeks in a knee osteoarthritis population, both suggest retatrutide has a meaningful advantage over tirzepatide's 22.5% benchmark. The liver fat reduction data from the MASLD Phase 2 trial is in a category by itself.
But the evidence gap is real and clinically significant. Tirzepatide is FDA-approved with an extensive Phase 3 safety and efficacy dataset, real-world prescribing experience, and an established cardiovascular safety profile from SURPASS-CVOT. Retatrutide has one published Phase 2 trial, one Phase 3 topline readout from a specific patient population pending full publication, and no completed cardiovascular outcomes data.
The pragmatic conclusion: for patients seeking treatment today, tirzepatide represents the most powerful evidence-based option available through established clinical channels. Retatrutide represents where the field is heading and merits serious attention — particularly for patients with severe obesity, hepatic steatosis, or insufficient response to dual agonism. When it reaches approval, likely in 2027, the clinical landscape will likely shift again. Until then, the best available treatment is the one that is actually available.